Medical devices & diagnostics · Supportive oncology
Luminate Medical
A Galway company building wearables that press the blood supply shut around hair follicles and nerves so chemotherapy reaches less of them. Two devices are in US trials; neither is FDA cleared. While it waits, the company has become a home infusion provider.
A cap you can leave in
A woman with stage 2 breast cancer sits down for her first round of doxorubicin and cyclophosphamide. A nurse fits a soft cap over her scalp and small pumps inflate it. Pressure outside the tiny vessels feeding her hair follicles rises past the pressure inside, and those capillaries collapse. Less drug reaches them, and less oxygen, so what does get through reacts less.
Under the trial protocol the cap stays on through the infusion and for at least two hours after it, up to four. Then she puts it in her bag and goes home with it.
That is the commercial argument. The devices that already hold FDA clearance for this job work by cold, not pressure, and are plumbed into a refrigeration unit on the clinic floor. Aaron Hannon, Luminate’s chief executive, put it to CNN in 2024: “One is that the machines are large and physically anchored in place, which means patients are getting treated for hair loss before, during and after each chemo session, spending two or three times as long in the hospital as they would be otherwise.”
What the hair is worth
About 65 percent of people on chemotherapy lose hair, and in breast cancer the figure approaches every patient. In a 2019 survey cited by CNN, 56 percent called it the worst side effect. Some refuse treatment over it.
The field is not empty. Dignitana’s DigniCap came through the FDA de novo pathway in December 2015 on a study of 122 women with stage I and II breast cancer, more than 66 percent of whom reported losing less than half their hair. Paxman’s cooler was cleared in April 2017 on a randomised trial in 182 women at seven US sites: at interim analysis, 48 of 95 cooled patients kept their hair against none of the controls. Both were later cleared for solid tumours generally, and Medicare coverage followed through CPT codes in 2021 and a first regional determination in 2023. The benchmark is a cleared, reimbursed category built on randomised evidence. Luminate is arguing on logistics and comfort as much as on efficacy.
A lab bench in Galway
Hannon was a Trinity College Dublin engineering student who had already built an assistive headset for people who could not shave unaided. Martin O’Halloran, professor of medical electronics at what was then NUI Galway and director of its Translational Medical Device Lab, brought him in. At the next desk sat Bárbara Oliveira, a biomedical engineer from Lisbon finishing a PhD on breast cancer imaging.
They asked patients what mattered. “We were just astonished at how much hair loss dominated the conversation,” Hannon told TechCrunch in 2021. He dropped out at 20, took a $100,000 Thiel Fellowship, and the three started the company on Enterprise Ireland commercialisation money. By February 2021 roughly €600,000 had gone into the device. Lilac, a glove and boot set, later applied the same trick to the peripheral nerves.
The pivot hiding inside the pitch
Between 2024 and 2026 the story changed shape. Luminate raised a $15 million Series A in September 2024, extended it by $2.5 million in December, and expanded it by $21 million in January 2026, taking company-stated total funding past $50 million. The money is not mainly going into caps and gloves.
It is going into Lotus: nurse-led chemotherapy infusions delivered in patients’ homes, with prescribing and dispensing left inside the patient’s own clinic. The website already lists the agents it will carry, from pembrolizumab to trastuzumab. The plan is forty partner clinics, then a patient-operated auto-injector.
Read one way, this is the logical end of the thesis: you cannot send chemotherapy home until you can manage the side effects that force people back into clinics. Read another way, a device company that has not yet cleared a device has started a services business that can earn revenue today.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| FDA status | No 510(k), de novo or PMA record under Luminate in openFDA as of Sep 23, 2026. A trial site release states the Lily device “is an investigational device and is not currently cleared by the FDA for sale in the United States.” | Public record |
| The cleared comparison | Scalp cooling is its own FDA device type, product code PMC, class II, regulation 878.4360. DigniCap: de novo DEN150010, Dec 2015, then K170871, Jul 2017. Paxman: K163484, Apr 2017, then K173032, Jun 2018. | Public record |
| PREVAIL, as registered | NCT06786078. Single group, open label, no control arm, no masking. Enrolment 85 estimated. Start Dec 20, 2024. Primary endpoint: CTCAE v5.0 grade 1 or less alopecia after four cycles, judged by an independent healthcare professional. Breast cancer stage 1 to 3 only. | Public record |
| PREVAIL, the record itself | Last updated Jan 22, 2025 and still listed as recruiting, with an estimated primary completion of July 2025 now over a year past. Five sites listed, none the Ohio centres that publicly dosed the first US patients in March 2025. | Record stale |
| IMPACT, the Lilac trial | NCT07142304. Randomised, parallel, quadruple masked, with a sham device identical but for the compression level. Enrolment 142 estimated. Start Oct 3, 2025. Primary endpoint: a rise of 5.06 points or more on the EORTC QLQ-CIPN20 at week 12. Eighteen sites listed, including St James’s Hospital Dublin. | Public record |
| Claimed efficacy | About 75 percent of patients had no hair loss in European first-in-patient testing, and about 80 percent hair retention preclinically. TechCrunch reported the early trial covered “only a handful of patients.” | Company-stated |
| Publication | No PubMed results for the company or either device in the Sep 23, 2026 records pull, and the European work is not in the registered trial records retrieved. | Not found |
| Non-dilutive funding | Three DTIF awards, company-stated at €2.1M, €4.4M and €6.4M, the last confirmed by reporting of the April 2025 government announcement. An EIC Accelerator award in June 2023, amount for Luminate not published. | Public record |
| Founding date | Press releases say 2018. The company timeline and its Y Combinator profile say 2019. Forbes reported a January 2020 launch. The SEC filer entity gives 2021. | Claims differ |
Read plainly: the neuropathy programme is where the evidence is being generated. IMPACT is randomised and sham controlled against a validated patient-reported instrument, the design a regulator and a payer both want. The hair loss programme, the one that gets the headlines, rests on an open label single arm study whose registry entry has not moved in twenty months, plus company figures from a handful of European patients that no journal has reviewed.
What to watch
- Whether the PREVAIL record is updated. MedTech Strategist reported in February 2026 that the trial was expected to wrap up by the end of this year.
- IMPACT topline. Primary completion was estimated for August 2026, and in January 2026 the company said neuropathy data was expected by the middle of the following year.
- A first FDA submission, and which device it covers. Scalp cooling has its own product code and predicates; a compression device does not obviously fit them.
- Reimbursement, and whether Lotus infusion revenue arrives before device revenue. Scalp cooling took from 2015 to October 2023 for a first Medicare determination.
In their words
“we were just astonished at how much hair loss dominated the conversation”
Aaron Hannon, CEO and co-founder, TechCrunch, 2021 · Independent
“Hair loss is one of the most traumatic aspects of cancer treatment, and scalp cooling is currently the main treatment method, but it’s incredibly painful”
Aaron Hannon, The Irish Times, February 2021 · Independent
“So the vision is to create a treatment for the side effects of cancer treatment like Hair Loss, that’s just as easy as buying a wig.”
Aaron Hannon, LSI USA ’23 interview · Interview
“What you might not know is that cancer care can also mean irreversible nerve damage to your hands and feet, affecting your job or your chances of sustaining a life-extending drug.”
Bárbara Oliveira, co-founder, Silicon Republic, 2023 · Independent
“We haven’t had any serious adverse events related to the device, so safety has been pretty good.”
Aaron Hannon on the European testing, CNN, 2024 · Company-stated
“Patients in the past may have struggled to agree to a certain treatment if they knew that they were going to lose their hair.”
Andrea Smith, nurse leader, Memorial Sloan Kettering, to CNN, 2024 · Independent
“In the UK, delays of just four weeks in starting treatment can increase mortality by 10 per cent.”
Aaron Hannon, The Irish Times, June 2025 · Independent
Related companies
Sources
- Public recordClinicalTrials.gov NCT06786078 (PREVAIL) and NCT07142304 (IMPACT)
- Public recordopenFDA 510(k) and classification queries, code PMC
- Public recordDe novo DEN150010; 510(k) K170871, K163484, K173032
- Public recordForm D, Luminate Medical Inc., CIK 0002022415
- Public recordEIC Accelerator win for four Enterprise Ireland clients
- IndependentCancer and neonatal treatments funded under DTIF
- IndependentTwo Luminate reports by Devin Coldewey
- IndependentThis helmet could help stop hair loss during cancer treatment
- IndependentIlluminating quality of life during cancer care
- IndependentA solution to chemo hair loss and other Irish innovations
- IndependentMedical devices that could let cancer patients treat themselves at home
- IndependentIrish startup preventing hair loss during chemotherapy raises $5 million
- IndependentLuminate Medical Wraps Its Arms around Cancer Care
- InterviewAaron Hannon spotlight interview
- IndependentExpanding the Availability of Scalp Cooling
- CompanyLuminate Raises $21 Million to Expand Home Cancer Treatment
- PartnerMercy Health oncology program joins the Lily trial
- CompanyLuminate website, about and services pages
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
